Genmab extends HuMax-CD4 CTCL trial
Danish biotechnology firm Genmab AS has amended the design of an ongoing study of HuMax-CD4 (zanolimumab) in refractory cutaneous T-cell lymphoma. The trial, which had previously only included patients with the mycosis fungoides form of the disease, will now recruit sufferers of Sezary syndrome, a second type of CTCL.
Additionally, as a result of the higher-than-expected response rates that have been observed in the 14mg/kg dose group, Genmab has decided to discontinue the 8mg/kg section of the trial. Lisa Drakeman, the company's chief executive, said that expansion of the program would expedite enrollment, in addition to providing more benefit to patients.
In related news, HuMax-CD4 has received Orphan Drug designations for refractory CTCL from regulators in Australia, and for refractory nodal T-cell lymphoma in Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze